NCT07778836招募中3 期
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects With Friedreich's Ataxia
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 150
- 试验地点
- 3
- 主要终点
- Change from baseline in Upright Stability Score (USS) subscale E of modified Friedreich's Ataxia Rating Scale (mFARS) at Week 72 (Region-specific)
研究概览
简要总结
To evaluate the efficacy and safety of subcutaneous nomlabofusp in adult and pediatric subjects with Friedreich's ataxia
详细描述
This is a global, randomized, multi-center, placebo-controlled study to investigate the efficacy and safety of nomlabofusp in subjects with Friedreich's ataxia
The main objectives of the study are to evaluate:
- The efficacy of subcutaneous (SC) administration of nomlabofusp compared to placebo at Week 72; 1) on the Upright Stability Score (USS) Subscale E of the Modified Friedreich's Ataxia Ratings Scale (mFARS), or 2) mFARS total score (Region specific objective)
- The efficacy of SC administration of nomlabofusp compared to placebo at Week 72 on the Clinical Global Impression of Severity (CGI-S) score
- The safety and tolerability of SC administration of nomlabofusp
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 12 Years 至 40 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects who meet all of the following criteria are potentially eligible for study participation:
- •Subject must provide genetically confirmed FRDA diagnosis report and is homozygous for GAA repeat expansions documented on the genetic diagnostic report, with repeat sizing (if available).
- •Subject must complete 1 trial at Screening and 1 trial at Day -1 of the T25-FW test, using their customary assistive device (e.g., cane, 2 canes/crutches [Canadian crutches], wheeled walker/rollator or canine assistance) if needed. Each trial must be completed within 3 minutes.
- •Subject must have the following at Screening and Day -1 per the following upright stability items from Module E of the mFARS:
- •Item #E1, Sitting Posture - no more than a maximum score of 2
- •Item #E2A, Stance Feet Apart - no more than a maximum score of 2 (average of 3 attempts)
- •Subject must have an mFARS score ≥ 20 and < 60 at Screening and Day -
- •Subject must have a Functional Staging for Ataxia score of 4 or less at Screening.
- •Subject demonstrates sufficient dexterity and visual acuity to prepare and self-administer SC injections of study drug daily (QD) or has an identified caregiver who will be trained and committed to prepare and administer the injections.
- •Subject has a Screening HbA1c ≤ 7.0%.
- •If the subject is taking permitted concomitant medication(s), subject must have been on a stable dose and frequency of medication(s) over the past 28 days prior to initiation of Screening. Subjects taking niacin and resveratrol must have been on a stable dose and frequency for 90 days prior to initiation of Screening and subjects taking omaveloxolone must have been on a stable dose and frequency for 1 years prior to initiation of Screening.
排除标准
- •Subjects are excluded from the study if any of the following exclusion criteria are met:
- •Subject who is confirmed as compound heterozygous (GAA repeat expansion on only 1 allele) for FRDA.
- •Subject previously participated in a clinical trial involving nomlabofusp. Participation is defined as the subject having signed the informed consent for the study and received at least 1 dose of study drug (nomlabofusp or placebo).
- •The subject has any condition, disease, or situation that could confound the results of the study or put the subject at undue risk, making participation inadvisable in the opinion of the PI.
- •Women of childbearing potential who are pregnant (have a positive pregnancy test at Screening or Day -1), lactating, or planning to attempt to become pregnant during this study or within 90 days after the last dose of study drug (this includes male subjects with partners of childbearing potential who are attempting to become pregnant).
- •Subject used any investigational drug or device within 90 days prior to the initiation of Screening.
- •Subject previously received a gene therapy (investigational or approved) at any time in the past.
- •Subject requires use of amiodarone.
- •Subject used erythropoietin, etravirine, or gamma interferon within 90 days prior to the initiation of Screening.
- •Subject's use of biotin supplementation exceeds 30 μg/day, either as part of a multivitamin or as a standalone supplement, within 7 days prior to the first dose of study drug. Biotin supplementation ≤ 30 μg/day is permitted if taken at a stable dose and frequency for at least 28 days prior to the initiation of Screening and there is a commitment from the subject to maintain the biotin dose throughout the study (due to interference with assays).
- •Subject receives medication that requires SC injection in the abdomen or thigh.
- •Subject has a Screening ECHO left ventricular ejection fraction < 45%.
- •Subject has a QTcF on an ECG as specified below:
- •For subjects ≥ 12 and < 18 years of age, a male or female subject with a QTcF > 460 ms.
- •For subjects ≥ 18 years of age, a male subject with a QTcF > 450 ms or a female subject has a QTcF > 470 ms.
- •Subject has suicidal ideation as determined by a "yes" to item #2 on the C-SSRS at Screening (within the last 28 days) or at Day -1.
研究组 & 干预措施
Nomlabofusp
Experimental
Daily subcutaneous injection of nomlabofusp for 72 weeks
干预措施: Nomlabofusp (Drug)
Placebo
Placebo Comparator
Daily subcutaneous injection of placebo for 72 weeks
干预措施: Placebo (Drug)
结局指标
主要结局
Change from baseline in Upright Stability Score (USS) subscale E of modified Friedreich's Ataxia Rating Scale (mFARS) at Week 72 (Region-specific)
时间窗: Baseline, Weeks 12, 24, 36, 48, 72
Number - The USS has a score range from 0 to 36. Lower scores mean less impairment and higher scores mean greater neurological impairment.
Change from baseline in the total modified Friedreich's Ataxia Rating Scale (mFARS) at Week 72 (Region-specific)
时间窗: Baseline, Weeks 12, 24, 36, 48, 72
Number - The mFARS has a total score range from 0 to 93. Lower scores mean less impairment and higher scores mean greater neurological impairment.
次要结局
- Change from baseline in the Clinical Global Impression-Severity (CGI-S) score at Week 72(Baseline, Weeks 12, 24, 36, 48, 72)
研究者
研究点 (3)
Loading locations...
相似试验
招募中
1 期
Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN2230 in Healthy ParticipantsHealthy Adult ParticipantsNCT07352423Alexion Pharmaceuticals, Inc.48
尚未招募
1 期
A Study of SGB-7342 in Subjects With Obesity or OverweightNCT07324850Suzhou Sanegene Bio Inc.45
招募中
不适用
A research study comparing how well different doses of the medicine NNC0662-0419 lower blood sugar in people with type 2 diabetes (NA)Type 2 diabetesjRCT203125082825
已完成
2 期
Safety and Efficacy of Topical AT-004 1% in Participants With Acne Vulgaris (AV)Acne Vulgaris on the FaceNCT07774364Arctic Therapeutics63
已完成
3 期
Evaluate the Efficacy, Safety, and Pharmacokinetic Profile and Immunogenicity of Subcutaneous Netakimab in Chinese Adult Patients With Active Ankylosing SpondylitisAnkylosing SpondylitisNCT07277179SPH-BIOCAD (HK) Limited113